Brokers Issue Forecasts for HealthEquity Q2 Earnings

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Research analysts at Barrington Research decreased their Q2 2026 earnings per share estimates for shares of HealthEquity in a note issued to investors on Thursday, June 5th. Barrington Research analyst A. Paris now forecasts that the company will post earnings per share of $0.72 for the quarter, down from their prior estimate of $0.73. Barrington Research currently has a "Outperform" rating and a $125.00 target price on the stock. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share. Barrington Research also issued estimates for HealthEquity's Q3 2026 earnings at $0.72 EPS and Q4 2026 earnings at $0.78 EPS.

Several other analysts also recently weighed in on the company. Wells Fargo & Company boosted their price objective on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. The Goldman Sachs Group boosted their price objective on HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a research report on Wednesday, June 4th. Raymond James upgraded HealthEquity from an "outperform" rating to a "strong-buy" rating and lowered their price objective for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. KeyCorp lowered their price objective on HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Finally, Bank of America boosted their price objective on HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $118.09.

HealthEquity Stock Performance

NASDAQ:HQY opened at $111.55 on Monday. The business has a 50 day moving average of $91.48 and a 200 day moving average of $97.72. The company has a market capitalization of $9.65 billion, a price-to-earnings ratio of 102.34, a PEG ratio of 1.60 and a beta of 0.49. HealthEquity has a 1-year low of $65.01 and a 1-year high of $116.65. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million during the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter in the previous year, the company posted $0.80 EPS.

Insider Activity at HealthEquity

In related news, EVP Michael Henry Fiore sold 8,881 shares of the company's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the sale, the executive vice president now directly owns 56,655 shares of the company's stock, valued at $4,433,820.30. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the sale, the director now directly owns 84,969 shares in the company, valued at approximately $6,597,842.85. The trade was a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On HealthEquity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its stake in shares of HealthEquity by 0.3% in the fourth quarter. Ameritas Investment Partners Inc. now owns 33,856 shares of the company's stock worth $3,248,000 after acquiring an additional 88 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of HealthEquity by 34.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after acquiring an additional 98 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in shares of HealthEquity by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 24,200 shares of the company's stock worth $2,322,000 after acquiring an additional 100 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of HealthEquity by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 17,776 shares of the company's stock worth $1,706,000 after acquiring an additional 100 shares during the last quarter. Finally, State of Michigan Retirement System grew its stake in shares of HealthEquity by 0.5% in the fourth quarter. State of Michigan Retirement System now owns 20,722 shares of the company's stock worth $1,988,000 after acquiring an additional 100 shares during the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.